SCBIO believes growing the life sciences sector will significantly transform the state’s economy. see more
Compliments of the Community Journal...
It was all smiles on Sept. 30 as BMW marked the 25th anniversary of the first vehicle to roll off its Spartanburg assembly line, a singular moment that dramatically transformed the economic face of South Carolina.
A quarter-century after opening, the German manufacturer’s North American facility employs more than 11,000 workers who build 1,500 vehicles daily, a pace requiring the services of more than 40 main suppliers across the state.
The average wage among all S.C. jobs supported by the automotive industry stood at $64,120 in 2017 compared to $40,293 across all employment categories, say findings commissioned by the South Carolina Biotechnology Industry Organization (SCBIO).
Now three years old, SCBIO is spearheading an aggressive initiative to make South Carolina the preferred location for new or expanding companies in another highly promising industry: life sciences. Read the entire story by clicking here.
SCRA added three advisory groups for biomedical sciences, cybersecurity and industry see more
Summerville, S.C.—South Carolina Research Authority (SCRA) announces the formation of three Business and Science Advisory Boards (BSABs). The purpose of the BSABs is to advise SCRA’s Board of Trustees when requested by it. The boards include representatives from South Carolina research universities, the venture capital/angel investment community, South Carolina Department of Commerce, and industry leaders in the following areas:
Each board provides key business and technical expertise, acts as an independent/ unbiased sounding board for input on SCRA’s program implementation and performance and provides guidance to SCRA regarding funding opportunities. One upcoming funding opportunity on which the BSABs will advise is the SCRA-Academia Collaboration Team (SACT) Collaborative Research Grants. These grants will be available for multi-institutional, collaborative research teams that seek to advance commercially relevant research and address key industry challenges to foster technology-enabled growth of the state’s innovation economy. The solicitation will be released in June.
“SCRA serves as a bridge between industry and academia. It is imperative that the applied research SCRA funds benefits not only its academic stakeholders, but also South Carolina’s industrial base. The development of the BSABs ensures that the new SACT program achieves those objectives for both stakeholder groups,” said Christine Dixon Thiesing, SCRA Director of Academic Innovations.
The SCRA fuels South Carolina’s innovation economy by accelerating technology-enabled growth in academia, entrepreneurship and industry. SCRA works with public and private sectors, including industry, to identify market trends and validate the commercial relevance of academic research that SCRA funds. SCRA’s programs and operations had an almost $700 million impact on the state’s economy during the last fiscal year.
Chartered in 1983 by the State of South Carolina as a public, nonprofit corporation, SCRA fuels South Carolina’s Innovation Economy by accelerating technology-enabled growth in research, academia, entrepreneurship and industry.
Clemson, Prisma Health to collaborate on developing new medical treatments see more
Researchers at Clemson University and Prisma Health have received funding to collaborate on the development of new medical treatment and diagnostic technologies.
Three Clemson-Prisma Health collaborations received investments from the recently created Innovation Maturation Fund, a joint effort between the Health Sciences Center (HSC) at Prisma Health and the Clemson University Division of Research. The program provides health care-focused grants designed to advance the development and commercialization of innovative medical initiatives and translational science, to improve the health care industry and to promote economic growth in the region.
The projects supported by this fund include a system to monitor triggers affecting respiratory health, injectable tissue regeneration technology and a monitoring device for patients with chronic kidney disease.
This year’s Innovation Maturation Fund awards range from $20,000 to $35,000 and were granted to:
Brian Booth, assistant professor in the department of bioengineering, and Jeffery Edenfield, medical director at the Prisma Health Institute for Translational Oncology Research (ITOR), to further develop a collagen-type medical implant that could greatly aid in breast tissue regeneration post-lumpectomy and prevent the recurrence of tumors.
Goutam Koley, professor in the department of electrical and computer engineering, and Steve Snodgrass, pediatric pulmonologist, to develop a mobile sensor system that monitors environmental triggers for respiratory health issues that are especially prevalent in patients with respiratory illnesses. The monitoring system will utilize a battery powered miniaturized sensor system with cellular data connectivity that can be carried in person to continuously monitor specific environmental parameters for an individual.
Robert Latour, McQueen-Quattlebaum Professor in the department of bioengineering, and Sudha Garimella, clinical assistant professor in the School of Health Research and medical director of the Division of Pediatric Nephrology and Hypertension at Prisma Health–Upstate, t0 continue to develop ammonia breath-test sensors that can be used by patients with chronic kidney disease (CKD) to measure the ammonia concentration in their exhaled breath. This technology would enable patients with CKD to monitor their physiologic status within the comfort of their own homes.
Managed by the Clemson University Research Foundation, the goal of the fund is to increase applied research collaborations between Clemson faculty, graduate students and Prisma Health clinicians and to promote ideation and design of medical technology innovations that are attractive for commercialization.
“The Innovation Maturation Fund is a special funding program that was developed in conjunction with the Clemson Division of Research and Prisma Health to target unmet needs in the health care industry,” said Chris Gesswein, executive director of the Clemson University Research Foundation. “I am excited to be able to participate in granting the first round of funds to deserving researchers through this new program. An important step towards fostering and supporting innovation in health sciences, with this program we have the unique opportunity to accelerate the commercialization of medical technologies in an effort to create a more self-sustaining model for promoting growth in health care.”
“Prisma Health is excited to partner with Clemson University to engage companies and researchers in developing the next innovative breakthroughs in healthcare,” said Cody Reynolds, technology transfer manager in the Office of Innovation at Prisma Health-Upstate. “The Innovation Maturation Fund provides early-stage technical solutions to clinical opportunities and access to clinical learning environments that will equip researchers with the tools necessary to successfully obtain public and private funding.”
Arthrex has completed construction on their new South Carolina manufacturing facility see more
Brasfield & Gorrie recently completed construction on a new manufacturing facility in Anderson for Arthrex, a global orthopedic medical device company headquartered in Naples, Florida.
The $36.1 million project includes a 250,000 square foot medical device manufacturing building and a 30,000 square foot central services building. The manufacturing building consists of 175,000 square feet of manufacturing floor space and 20,000 square feet of clean room assembly space for sterile packaging activities for all manufactured medical devices. The remainder of the building is a two-story office space for support staff. Click here for the full story.
South Carolina Life Sciences Conference to Feature J&J Innovation Leader Michal Preminger, Over 40 National SpeakersSCBIO 2019 Conference Draws Speakers, Takes Center Stage October 29-31 see more
Conference registrations soar with sell-out expected; CEOs and top industry leaders from 30 states and countries expected in Greenville for strategic partnership development, industry insights
SOUTH CAROLINA – September 11, 2019 – Johnson & Johnson Innovation Leader Michal Preminger will join more than 40 additional national speakers at SCBIO 2019 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to South Carolina October 29-31.
Following an October 29 welcome reception showcasing downtown Greenville, Ms. Preminger will address an expected sold-out conference at the Hyatt Regency with a keynote presentation entitled “Innovation for a Better Tomorrow” as the main program gets underway the morning of October 30. Her presentation will be followed by a high-powered panel comprised of regional healthcare executives entitled “Optimizing the Future of Healthcare in SC and Beyond.”
Among other featured Conference programs are EY’s “NextWave Wellness: An Interactive View of the Future of Our Industry”, and an address by South Carolina Lieutenant Governor Pamela Evette entitled “South Carolina: Just Right for Life Sciences.” Clemson University President Jim Clements headlines Day 2 with an address entitled “The Power of Partnerships in Fueling Life Sciences”, while Medtronic global executive Christian Howell will address “Driving Value-Based Care Through Collaboration".
Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2019, with registration nearly doubling the record-setting pace of 2018. Other committed speakers and panelists include IQVIA Institute of Health Data Science SVP Murray Aitken, Innova Therapeutics CEO and Founder Robert Ryan, ChartSpan CEO & Founder Jon-MIchial Carter, Firststring Research President Dr. Gautam Ghatnekar, Nephron Pharmaceuticals CEO Lou Kennedy, USC President (Ret.) Harris Pastides, PhRMA Senior Regional Director Thomas Hardaway and numerous others. More than 20 programs will be featured over two days.
Themed “Ignite The Future!”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion. Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio-ag and more. Space is limited and advance registration is still available at https://www.scbio.org/cpages/register-now-for-scbio-2019.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has a $12 billion economic impact in the Palmetto State, with more than 670 firms directly involved and over 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
SCBIO 2019 kicks off Tuesday evening October 29 with a Grand Opening Reception for conference registrants, speakers and sponsors at Greenville’s ONE Center, presented by Prisma Health. Wednesday will feature a complete day of sessions beginning at breakfast and continuing through an evening reception presented by the Greenville Area Development Corp., Greenwood Partnership Alliance and City of Greenville. The conference will conclude Thursday at lunchtime.
“Life sciences is a major driver of South Carolina’s economy, and this conference’s growth is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2019.”
Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more. All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance, Economic Development Partnership and SiMT.
As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – along with PhRMA and AdvaMed, SCBIO members include academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world. For additional information on SCBIO, visit www.SCBIO.org.
Life sciences in South Carolina is big business -- and getting bigger by the day. Read why... see more
In this article published simultaneously in Charleston Business Magazine, Columbia Business Magazine and Greenville Business Magazine, SCBIO CEO Sam Konduros paints a picture of the diversity of the rapidly-growing life sciences industry, and why the future is exceedingly bright -- and getting brighter -- as the $11.4 billion industry soars to new heights across South Carolina.
Life sciences in South Carolina spans a diverse spectrum—from major pharmaceutical companies to globally known medical device companies.
It encompasses start-ups and early stage innovation companies and embraces prestigious research universities and acclaimed health care systems employing some of America’s finest minds. It includes research and medical labs, bioscience-related distribution, even Bio-Ag tied to the state’s historical agricultural segment. Click to read complete article...
Clemson and Arthrex are launching a program to teach students and support the med device industry see more
The surgical device industry is continuously growing and evolving. According to data from GlobalData, the orthopedics market is expected to grow to $66 billion by 2023 from $52.8 billion in 2017. In South Carolina, medical devices are an anchor of the state's fast-growing and globally respected life sciences industry, according to executives with SCBIO -- the Palmetto State's life sciences industry organization and champion.
In response to this upward trend, surgical device companies are seeking more employees with a specialized skillset, and thanks to a new partnership with Arthrex Inc., Clemson University students will be equipped to answer the call.
A global leader in minimally invasive orthopedics, Arthrex already works with Clemson on a number of research projects. Now it’s expanding its engagement with the university through a new, two-year pilot program developed with the needs of the surgical device industry in mind and a generous gift of ten $7,500 scholarships.
“Arthrex is one of the university’s valuable strategic partners, and this opportunity to work together to create programming unique to Clemson speaks volumes about what the company thinks of our talented faculty and students,” said Clemson President James P. Clements. “This partnership is another example of Clemson’s ongoing commitment to the state of South Carolina, and I am grateful to Arthrex for its generous gift, which will enable our students to work with a world-class company to develop skills that are vital to the surgical device industry.”
“Arthrex takes great pride in its commitment to education and we are pleased to help develop the next generation of highly skilled professionals like Arthrex Technology Consultants who work with orthopedic surgeons to provide trustworthy technical product support,” said Arthrex President and founder Reinhold Schmieding.
In October 2017, Arthrex announced plans for a new $40 million facility in Sandy Springs, South Carolina. Surgical devices will be manufactured in the 290,000-square-foot facility, which is scheduled to open this summer. The new location is part of Arthrex’s efforts to expand its manufacturing base into South Carolina to create new products and jobs in America.
The pilot program will span two years and comprise a series of courses, Arthrex internships and additional learning opportunities for rising third-year students majoring in bioengineering, marketing and health sciences departments.
MKT 4950 Developing and Selling Medical Devices is the first course being offered in the series and will begin in fall 2019. Taught by Ryan Mullins in the College of Business, course material provides students an introduction to the health care industry with a focus on the development and marketing of surgical device innovations. Mullins was selected to develop the course as the Provost’s Inaugural Innovation Fellow, a program created to encourage faculty on campus to support corporate engagement efforts.
“Our collaboration with Arthrex helps us create a new type of focused course,” said Mullins. “We will walk students through real case studies at Arthrex to understand how surgical devices get translated from marketable idea to surgeon or physician adoption. This helps us illustrate the challenges inherent to both the health care marketplace and marketing of new offerings, which is not taught anywhere else.”
Students who are enrolled in the course may apply for the scholarship and additional programs offered as part of the two-year series of courses. Those who would like to participate in the entire program will take Student Affairs’ Certified Student Leader Program in the spring and an internship with Arthrex in the summer. Students outside of the participating departments can also intern with Arthrex by working with their advisers and the career center.
This partnership was developed through Clemson’s Office of Corporate Partnerships and Strategic Initiatives. Additional details regarding the scholarship, internship and second-year courses will be available soon.
Learn about South Carolina Life Sciences Feb. 20! see more
Industry subject matter experts to cover what businesses need to know
about life sciences, South Carolina’s fastest-growing industry segment
GREENVILLE, SC – February 4, 2019 – SCBIO will host a full day program February 20, 2019 -- Life Sciences Boot Camp: Insights on SC’s Fastest-Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.
To be held at the University of South Carolina’s Alumni Center in Columbia, the program will run from 8:30 a.m. until 4:30 p.m. and will feature a light breakfast followed by presentations from over half a dozen noted life sciences industry leaders. Confirmed presenters and their topics are:
- Tushar Chikhliker, Partner, Nexsen Pruet, “Pharma Industry Challenges Opportunities & Legal Insights”
- Kathy Phlegar, Principal, Phlegar & Associates, “Product Development and Commercialization: The Changing Landscape of Bringing MedTech Products to Market”
- Maureen Thomas, National Institute on Aging/National Institutes on Health, “Early Stage Funding: Accessing SBIR-STTR Capital”
- Erica Jackson, Partner, K&L Gates, “Navigating the FDA: An Overview of Medical Product Approvals and Enforcement Trends”
- Dave McGlashan, Life Sciences Team Architect, DPR Construction, “Optimizing Capability & Efficiency in Your Life Sciences Facility”
- Darralyn Alexander, President, Reimbursement Strategies – “How To Gain Reimbursement For My New Technology”
- Sam Konduros, President & CEO, SCBIO – “South Carolina Life Sciences 2019: A Look Forward”
SCBIO Investor Organizations receive one registration at no charge, and additional attendees from Investor organizations pay only $50 for the entire day. Individual Members of SCBIO pay only $50 for the entire program, while the general public and Non-Members can attend for just $125. To register or for more details, visit the Events page at www.SCBIO.org/.
An additional highlight of the day’s program on “Early Stage Funding: Accessing SBIR-STTR Capital” will be when presenter Maureen Thomas is joined for discussion and open Q&A by Tyler Tatum and Ron Gorman of 3PhaseSC – South Carolina’s only free resource for SBIR/STTR grant consulting. Attendees may also schedule 1-on-1 time for afternoon discussion with Ms. Thomas between 1:15 PM and 3:30 PM for more detailed conversation and guidance.
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries. Life sciences is recognized as the fastest-growing segment of South Carolina’s knowledge economy.
SCBIO is also the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO’s diverse membership is leading research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
For additional information on SCBIO, visit www.SCBIO.org.
Moterum selected to present at prestigious medtech conference in Chicago, IL see more
Southeastern medtech company develops mobility solutions for patients suffering from strokes, neural traumas; forum convenes investors seeking leading-edge advances in health and life sciences
GREENVILLE, S.C. – July 11, 2018 – Moterum Technologies Inc., a South Carolina-based mobility and gait rehabilitation development company, has been selected to present at the prestigious Cavendish BioHealth Impact Forum July 17-18, 2018 in Chicago, Illinois. The Forum provides an environment for organizations and investors to further their strategic social impact investing, grant-giving, and philanthropy programs in support of health and life sciences advances.
Co-hosted by Cavendish Global, the Shirley Ryan AbilityLab, and MATTER, the Forum showcases presentations and panel discussions by leading research institutions, private-sector companies, nonprofit organizations, and foundations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.
Moterum Technologies is one of 10 featured organizations invited to present their solutions at the Chicago Conference. An innovative medical technology development company, Moterum’s focus is designed to help resolve mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients how to re-learn walking in their own home.
“We are honored to be selected to present at the 2018 Chicago Forum, and value the recognition it will provide of our innovative approach to helping stroke survivors walk independently and without a limp or asymmetry,” said David Huizenga, CEO of Moterum Technologies. “Our device can be used at home and is fully connected and positioned for telehealth systems, making it a viable solution for developed and developing health systems alike. We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to improving the health and lives of people around the world.”
The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, and seeks to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.
“With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said J. Michael Moffat, Chairman of Cavendish Global. “The quality and originality of Moterum Technologies’ research and scientific insights in treating gait problems of stroke survivors positions them to make a major contribution to global health by helping stroke survivors retake an independent position in society.”
For further information on Moterum Technologies, visit www.moterum.com.
About Moterum Technologies Inc.
Moterum Technologies is an innovative medical technology development company that focuses on solving mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients to relearn how to walk in their own home.
South Carolina's life sciences industry is booming. Read on for details... see more
From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming. The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries. Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.
South Carolina life sciences gets another huge boost with BD's $150 million investment in Sumter see more
Medical technology company creating 125 new jobs
COLUMBIA, S.C. - BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a $150 million investment in its existing Sumter County manufacturing facility. The company is projected to create an additional 125 new jobs over the next several years.
Employing more than 65,000 associates worldwide, BD is one of the world's largest medical technology companies and supports health care providers in more than 190 countries. BD's Sumter County facility has been in operation since 1970, manufacturing blood collection devices that are critical to the health care industry.
Located at 1575 Airport Road in Sumter, S.C., BD's Sumter facility is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
The Coordinating Council for Economic Development has approved job development credits related to this project, as well as a $600,000 Set Aside grant to assist with the costs of road work and site preparation.
"For nearly 50 years, BD's Sumter facility has consistently delivered superior quality products, vital for our customers and their patients, through a talented and engaged workforce. We would like to thank TheLINK economic development alliance, Sumter Economic Development, the City of Sumter, Sumter County and the S.C. Department of Commerce for their continued support of BD and our employees as we continue to invest in the facility. We look forward to the ongoing success of our BD Sumter manufacturing team as they continue to advance the world of health." -BD Executive Vice President of Global Operations and Chief Supply Chain Officer Jim Borzi
"After opening in our state more than 40 years ago, we're thrilled that BD continues to grow and succeed here. This announcement once again demonstrates that South Carolina is a place where medical technology companies want to do business, and we welcome this new $150 million investment." -Gov. Henry McMaster
"Not only does our state excel in advanced manufacturing, we're also increasingly a top choice for companies in the life sciences sector. BD has been a strong member of Team South Carolina for decades, and we congratulate them on their ongoing success." -Secretary of Commerce Bobby Hitt
"BD has been a leading employer in this county since opening its doors in 1970. We are grateful for their continued investment in our community and our people." -Sumter County Council Chairman James McCain
"We have long-enjoyed BD as a key component in the fabric of our industrial portfolio. This investment demonstrates their trust in our leadership, their commitment to the success of their business and their belief in our ability to regenerate the talent needed to produce the quality of goods for which BD is known." -Sumter Economic Development Chairman Greg Thompson
FIVE FAST FACTS
- BD is investing in its existing Sumter County manufacturing facility.
- $150 million investment to create 125 new jobs.
- Employing more than 65,000 associates worldwide, BD is one of the largest medical technology companies in the world and supports health care providers in more than 190 countries.
- Located at 1575 Airport Road in Sumter, S.C., BD's facility manufactures blood collection devices for the health care industry.
BD is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit www.bd.com.
Southeastern life science organization join forces to promote entire region see more
SCBIO and six additional Southeastern U.S. life science and medtech groups are joining forces to better promote and advocate for the region.
The Southeastern Medical Device Association (SEMDA) on Wednesday announced the formation of an alliance with six individual state medtech and life science advocacy groups: BioAlabama, Bio Florida, Georgia Bio, ncbio, Life Science Tennessee and SCBIO.
“Industry and academic partners simply cannot invest enough in each individual state’s bio advocacy organization — nor travel to each organization’s annual event every single year,” SEMDA executive director Jason Rupp said in a news release.
“But they can come to SEMDA, where the entire region gathers every year bringing their leading investors, academic and industry partners including the best of their young, innovative, investable companies,” Rupp said.
No single state in the Southeastern U.S. can match the medical device and life science industry strength of the nation’s major hubs in California, Minnesota and Massacusetts. But taken together, the region is more competitive, according to industry advocates there.
“We are strongest as a region,” said Russell Allen, president and CEO of Georgia Bio. “If we are to advance medical technologies to improve care, reduce healthcare costs and create new jobs, our state associations must work closely together to connect innovators and share resources.”
The announcement was made at the inaugural 2018 SEMDA Medtech Conference May 2-4 in Greenville, S.C.
Greenville-based Zylö Therapeutics is utilizing regional chemical/mechanical engineering in new ways see more
Once home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech.
Born from technology developed at the Albert Einstein College of Medicine, Greenville-based Zylö Therapeutics is utilizing the regional chemical/mechanical engineering expertise and support network to improve drug and nitric oxide delivery through a proprietary sustained delivery system called Nanopods.
SEMDA Medtech to Showcase Over 20 High-Impact New Technologies, National Speakers at May 2-4 ConferenceLeading-edge innovators, top presenters headed for SEMDA's Medtech 2018 in South Carolina see more
Leading-edge innovators present for recognition, reward at annual gathering of Southeastern who’s who in medical technology, devices and diagnostics
Greenville, SC – April 27, 2018 – At least 23 organizations ranging from start-ups to well-established companies have been accepted to present their latest, ground-breaking innovations to entrepreneurs, innovators, angel investors and business leaders from across the life sciences space as the Southeastern Medical Device Association (SEMDA) 2018 Medtech Conference convenes in Greenville, SC May 2-4, 2018.
SEMDA -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has invited 23 finalist companies to present at PitchRounds 2018 – a highly targeted venue for both “Seed” companies as well as later-stage organizations to present innovative ideas to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others.
Companies from seven Southeastern states will present ground-breaking ideas and technologies to hundreds of industry leaders. Host state South Carolina leads the way with 10 companies invited to present, followed by Georgia and Florida with three companies each. North Carolina, Alabama, Virginia and Tennessee are also represented.
Among the South Carolina companies invited to present are Zylo Therapeutics, Accessible Diagnostics, KIYATEC and Moterum from host city Greenville, while Charleston’s Sanguine Technologies and Cryogenix, and Columbia’s Proof Biotechnologies are also invited.
Invitees from Georgia include Intent Solutions and nfant, both of Atlanta, while North Carolina entries include Diamond Othopedic of Charlotte. Memphis, Tennessee’s Sweetbio, Birmingham’s Circulogene and Nashville’s Raiven are also featured invitees.
Twelve Early-stage companies from the Carolinas, Alabama and Florida have been invited to present at PitchRounds, with four finalists to be selected to compete for $10,000 in prize money, while getting to meet investors and partners at sessions and networking receptions. SCBIO, SCRA and global law firm Eversheds Sutherland are co-sponsors of PitchRounds.
Among the featured speakers committed to present at the conference are keynoter Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.
Joe Lee is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Widely respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.
Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.
Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition. She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).
“The Southeastern medtech industry as a whole shows incredible growth and promise, and the diverse entries from across the region reflect that growth,” said Jason Rupp, Executive Director of SEMDA. “PitchRounds gives us the chance to see the future come to life before our eyes with cutting-edge innovation and game-changing advancements in medical technology, devices and diagnostics from some of America’s brightest minds.”
The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is strong but space is still available, noted Mr. Rupp. Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.
“These presenters and companies demonstrate that SEMDA has evolved into a truly regional organization that embraces and represents a diverse collective of medtech startups, universities, corporate organizations, investment resources, suppliers and capabilities from across the southeastern United States,” Mr. Rupp added.
The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.
Invited and scheduled to present at PitchRounds 2018
LATER STAGE (RAISING SERIES A OR LATER)
Kayla Rodriguez Graff
Sanguine Technologies Inc.
Accessible Diagnostics, LLC
Luke Marshall, Ph.D.
Aravis BioTech LLC
DiaTech Diabetes Technology
Proof Biotechnologies, Inc
PivotSC LLC/ XtremedX
A Charleston neighborhood is being transforned into a hotbed for life sciences firms see more
A plan from the early 2000s to transform part of Charleston’s Westside neighborhood into a hotbed for life sciences firms, medical device companies and innovative medical research is now in motion.
A large-scale development known as WestEdge is in the works on land bounded by Lockwood Boulevard, Fishburne Street, Hagood Avenue and Spring Street. A few hotels and office buildings, Brittlebank Park, Joseph P. Riley Jr. Park and expansive gravel parking lots dot that part of the Westside today.